Back to Search
Start Over
Cordycepin improves sensitivity to temozolomide in glioblastoma cells by down-regulating MYC.
- Source :
-
Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2023 Nov; Vol. 149 (17), pp. 16055-16067. Date of Electronic Publication: 2023 Sep 11. - Publication Year :
- 2023
-
Abstract
- Purpose: Glioblastoma is one of the malignant tumors with poor prognosis and no effective treatment is available at present.<br />Methods: To study the effect of cordycepin combined with temozolomide on glioblastoma, we explored the effect of the combination based on network pharmacology and biological verification.<br />Results: It was found that the drug combination significantly inhibited the cell growth, proliferation, migration and invasion of LN-229 cells. Drug combination inhibited epithelial-mesenchymal transition (EMT) by up-regulating the expression of E-cadherin and suppressing the expression of N-cadherin, Zeb1 and Twist1. Through network pharmacology, we further explored the molecular mechanism of drug combination against glioblastoma, and 36 drug-disease common targets were screened. The GO biological process analysis included 44 items (Pā<ā0.01), which mainly involved the regulation of apoptosis, cell proliferation, cell migration, etc. The enrichment analysis of KEGG pathways included 28 pathways (Pā<ā0.05), and the first four pathways were "MicroRNA in cancer, Proteoglycans in cancer, Pathways in cancer and PI3K-AKT signaling pathway". We detected the expression of important genes in the pathways and PPI network, and the results showed that the drug combination down-regulated NFKB1, MYC, MMP-9, MCL1, CTNNB1, and up-regulated PDCD4.<br />Conclusion: Cordycepin combined with temozolomide may down-regulate MYC through "MicroRNA in cancer, Proteoglycans in cancer, Pathways in cancer and PI3K-AKT signaling pathway", which in turn regulate the expression of MCL1, CTNNB1, MMP9, PDCD4, thus regulating cell proliferation, migration and apoptosis in glioblastoma.<br /> (© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Subjects :
- Humans
Temozolomide pharmacology
Temozolomide therapeutic use
Proto-Oncogene Proteins c-akt metabolism
Phosphatidylinositol 3-Kinases metabolism
Myeloid Cell Leukemia Sequence 1 Protein metabolism
Myeloid Cell Leukemia Sequence 1 Protein therapeutic use
Cell Line, Tumor
Cell Proliferation
Drug Combinations
Proteoglycans metabolism
Proteoglycans pharmacology
Proteoglycans therapeutic use
RNA-Binding Proteins
Apoptosis Regulatory Proteins metabolism
Glioblastoma drug therapy
Glioblastoma genetics
Glioblastoma pathology
MicroRNAs genetics
Subjects
Details
- Language :
- English
- ISSN :
- 1432-1335
- Volume :
- 149
- Issue :
- 17
- Database :
- MEDLINE
- Journal :
- Journal of cancer research and clinical oncology
- Publication Type :
- Academic Journal
- Accession number :
- 37695389
- Full Text :
- https://doi.org/10.1007/s00432-023-05347-0